Practical side of multistage clinical trials for screening new agents

Research output: Contribution to journalArticle

Abstract

Coordinating center operations are recommended for carrying out multistage phase II clinical trials in oncology. The relevant statistical issues in designing phase II trials are summarized. The predictive probability approach to multistage design is briefly described, along with an interactive computer program that facilitates design selection. A multistage trial monitoring form is described, along with data manager-biostatistician responsibilities for monitoring the trial for possible early termination. Procedures are recommended for dealing with patients who cannot be evaluated by response, for minimizing or eliminating selection bias introduced by clinician knowledge of interim results, and for minimizing clinician tendency to report responding patients sooner than those not responding.

Original languageEnglish (US)
Pages (from-to)71-75
Number of pages5
JournalCancer Treatment Reports
Volume67
Issue number1
StatePublished - Jan 1 1983
Externally publishedYes

Fingerprint

Clinical Trials
Phase II Clinical Trials
Selection Bias
Software

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Practical side of multistage clinical trials for screening new agents. / Herson, Jay.

In: Cancer Treatment Reports, Vol. 67, No. 1, 01.01.1983, p. 71-75.

Research output: Contribution to journalArticle

@article{0f9f714b2e11404ba0f9a641a82daa3f,
title = "Practical side of multistage clinical trials for screening new agents",
abstract = "Coordinating center operations are recommended for carrying out multistage phase II clinical trials in oncology. The relevant statistical issues in designing phase II trials are summarized. The predictive probability approach to multistage design is briefly described, along with an interactive computer program that facilitates design selection. A multistage trial monitoring form is described, along with data manager-biostatistician responsibilities for monitoring the trial for possible early termination. Procedures are recommended for dealing with patients who cannot be evaluated by response, for minimizing or eliminating selection bias introduced by clinician knowledge of interim results, and for minimizing clinician tendency to report responding patients sooner than those not responding.",
author = "Jay Herson",
year = "1983",
month = "1",
day = "1",
language = "English (US)",
volume = "67",
pages = "71--75",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Practical side of multistage clinical trials for screening new agents

AU - Herson, Jay

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Coordinating center operations are recommended for carrying out multistage phase II clinical trials in oncology. The relevant statistical issues in designing phase II trials are summarized. The predictive probability approach to multistage design is briefly described, along with an interactive computer program that facilitates design selection. A multistage trial monitoring form is described, along with data manager-biostatistician responsibilities for monitoring the trial for possible early termination. Procedures are recommended for dealing with patients who cannot be evaluated by response, for minimizing or eliminating selection bias introduced by clinician knowledge of interim results, and for minimizing clinician tendency to report responding patients sooner than those not responding.

AB - Coordinating center operations are recommended for carrying out multistage phase II clinical trials in oncology. The relevant statistical issues in designing phase II trials are summarized. The predictive probability approach to multistage design is briefly described, along with an interactive computer program that facilitates design selection. A multistage trial monitoring form is described, along with data manager-biostatistician responsibilities for monitoring the trial for possible early termination. Procedures are recommended for dealing with patients who cannot be evaluated by response, for minimizing or eliminating selection bias introduced by clinician knowledge of interim results, and for minimizing clinician tendency to report responding patients sooner than those not responding.

UR - http://www.scopus.com/inward/record.url?scp=0020661146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020661146&partnerID=8YFLogxK

M3 - Article

C2 - 6616494

AN - SCOPUS:0020661146

VL - 67

SP - 71

EP - 75

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -